Therapeutics Anti-Infective and Anti-Inflammatory Agents

Expanded findings from a randomized controlled trial of preconception low-dose aspirin and pregnancy loss

Mumford SL, Silver RM, Sjaarda LA, Wactawski-Wende J, Townsend JM, Lynch AM, Galai N, Lesher LL, Faraggi D, Perkins NJ, Schliep KC, Zarek SM, Schisterman EF

Published March 2016 Human reproduction (Oxford, England), 31(3), 657-665
DOI 10.1093/humrep/dev329 PMID 26759138 PMC PMC4755442

RRM Academy Synopsis

Preconception low-dose aspirin did not lower pregnancy loss risk

Daily low-dose aspirin, started before conception, did not lower the rate of pregnancy loss or change its type. A placebo-controlled trial followed 1228 women with one or two prior losses who took aspirin or placebo before trying to conceive. Among 1088 women who finished, 188 (17.3%) had a loss, split close to evenly between the two groups.

Key Findings

  • Among women who finished the trial, 96 of 537 (17.9%) on aspirin had a pregnancy loss, versus 92 of 551 (16.7%) on placebo (risk ratio 1.07, 95% CI 0.83 to 1.39).
  • Implantation failure, found through daily urine hormone testing, occurred in 28 of 537 (5.2%) on aspirin and 27 of 551 (4.9%) on placebo (risk ratio 1.06, 95% CI 0.64 to 1.78).
  • Clinically recognized pregnancy loss occurred in 68 of 537 (12.7%) on aspirin and 65 of 551 (11.8%) on placebo (risk ratio 1.07, 95% CI 0.78 to 1.48).
  • Of 82 clinically recognized losses tested for karyotype or chromosomal abnormalities, 29 (35.4%) were abnormal. An abnormal karyotype was not linked to aspirin use.
  • Aspirin and placebo showed no difference for any loss subtype studied, including pre-embryonic, embryonic, fetal, stillbirth, and ectopic losses.

Interpretation

The EAGeR trial followed 1228 women aged 18 to 40 with one or two prior pregnancy losses and no history of infertility in a placebo-controlled design. This report adds chart review, extra urine hormone tests to catch very early losses, and genetic testing of lost pregnancies. The added detail let researchers compare aspirin and placebo by stage of loss and by genetic type. The authors note that most participants were white with higher income and education than typical, which may limit how broadly the findings apply. The findings support further study of aspirin's role in specific groups, such as women with antiphospholipid antibodies.

RRM Context

Aspirin is widely used to treat recurrent pregnancy loss. Earlier reviews found a benefit mainly in women who carry antiphospholipid antibodies, a lab marker for an autoimmune clotting disorder. The EAGeR trial tested aspirin before conception, looking at loss types not studied before: implantation failure and losses with normal chromosomes. Restorative reproductive medicine centers on finding the specific cause of a loss. The findings fit that approach. Aspirin alone did not lower loss rates in this general group of women with a history of loss.

Abstract

Study Question

What is the association between daily preconception-initiated low-dose aspirin (LDA) treatment and very early pregnancy losses or euploid (chromosomally normal) losses among women with one to two prior losses?

Summary Answer

Daily LDA initiated preconception was not associated with the rate or type of pregnancy loss among women with a history of one to two prior pregnancy losses.

What Is Known Already

LDA is often used to treat recurrent pregnancy loss with reductions in pregnancy loss generally only observed among women with antiphospholipid antibodies, and null associations observed among women without antiphospholipid antibodies. We previously evaluated the association between LDA and pregnancy loss overall among women with one to two prior losses in the Effects of Aspirin in Gestation and Reproduction (EAGeR) trial and found no association, though did not distinguish between potential effects at different stages of pregnancy loss, including implantation failure, or between euploid and aneuploid losses.

Study Design, Size, Duration

The EAGeR trial was a multi-site prospective block-randomized double-blind placebo-controlled trial. In total, 1228 women were randomized to daily LDA (81 mg/day) plus folic acid (400 mcg/day), or placebo plus folic acid. Participants were assigned study drug for less than or equal to six menstrual cycles or if they conceived, throughout pregnancy with study drug discontinued at 36 weeks gestation. This analysis includes additional outcome information obtained from chart abstractions after the completion of the trial, as well as testing of stored urine for measurement of hCG and detection of very early pregnancy losses, and karyotyping of the products of conception for assessment of aneuploidy of the losses.

Participants/Materials, Setting, Methods

Women aged 18-40 with a history of one to two prior losses and actively trying to conceive were randomized (n = 615 LDA and n = 613 placebo) at four clinical centers in the USA (2007-2011). Log-binomial regression was used to estimate risk ratios under the intent-to-treat approach.

Main Results and the Role of Chance

Daily LDA initiated preconception was not associated with clinically recognized pregnancy losses or implantation failures among women with proved fecundity and a history of one to two prior losses. Specifically, 1088 (88.6%) women completed the trial with 797 having an hCG detected pregnancy (64.9%). Overall there were 133 clinical losses (12.7% LDA versus 11.8% placebo, P = 0.71) and 55 implantation failures (5.2% LDA versus 4.9% placebo, P = 0.89). No differences were found in rate of euploid losses (RR 1.11, 95% confidence interval: 0.99, 1.26).

Limitations, Reasons for Caution

Generalizability of these findings is limited to women with a history of one to two prior losses, and may further be limited to women of white race with higher socioeconomic status as given the rigors of the study protocol participants tended to be white and have higher incomes and more education. We were also missing karyotype information on approximately one-third of the clinically recognized pregnancy losses, which may limit our power to detect effects on euploid losses, though detailed sensitivity analysis showed similar results.

Wider Implications of the Findings

Our data do not support the general use of LDA to decrease pregnancy loss and further demonstrate no increased risk of loss for women on LDA treatment.

Study Funding/Competing Interests

This research was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland (Contract Nos. HHSN267200603423, HHSN267200603424, HHSN267200603426). The authors have no conflicts of interest.

Trial Registration

The trial was registered at ClinicalTrials.gov #NCT00467363.

Trial Registration

27 April 2007.

Date of First Patient's Enrollment

15 June 2007.

Topics

By this author

Related research

Therapeutics › Anti-Infective and Anti-Inflammatory Agents › Nonsteroidal Anti-Inflammatory Drugs · Pregnancy › Preconception Care › Preconception Optimization · Genetics and Immunology › Reproductive Immunology › Antiphospholipid Syndrome and Thrombophilia
Sunni L Mumford, Robert M Silver, Lindsey A Sjaarda, Jean Wactawski-Wende, Janet M Townsend, Anne M Lynch, Noya Galai, Laurie L Lesher, David Faraggi, Neil J Perkins, Karen C Schliep, Shvetha M Zarek, Enrique F Schisterman
S Mumford, Bob Silver, Rob Silver, Bobby Silver, R Silver, L Sjaarda, J Wactawski-Wende, J Townsend, A Lynch, N Galai, L Lesher, Dave Faraggi, D Faraggi, N Perkins, K Schliep, S Zarek, E Schisterman
PMID 26759138 26759138 DOI 10.1093/humrep/dev329 10.1093/humrep/dev329 Mumford et al. 2016, Mumford 2016